Scarica l'app Stockscreener
4.94
9.29%
0.42
Precedente Chiudi:
$4.52
Aprire:
$4.54
Volume 24 ore:
2.38M
Relative Volume:
0.93
Capitalizzazione di mercato:
$809.38M
Reddito:
-
Utile/perdita netta:
$-196.48M
Rapporto P/E:
-4.0632
EPS:
-1.2158
Flusso di cassa netto:
$-183.16M
1 W Prestazione:
+4.66%
1M Prestazione:
-5.18%
6M Prestazione:
+0.82%
1 anno Prestazione:
+111.11%
Intervallo 1D:
$4.54
$4.96
Intervallo di 1 settimana:
$4.46
$4.96
Portata 52W:
$1.85
$7.18
Annexon Inc Stock (ANNX) Company Profile
Nome
Annexon Inc
Settore
Industria
Telefono
(650) 822-5500
Indirizzo
1400 SIERRA POINT PARKWAY, BRISBANE
Compare ANNX vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ANNX
Annexon Inc
|
4.94 | 760.23M | 0 | -196.48M | -183.16M | -1.2158 |
VRTX
Vertex Pharmaceuticals Inc
|
458.99 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
607.93 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
892.26 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.72 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.77 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Annexon Inc Stock (ANNX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-23 | Iniziato | Chardan Capital Markets | Buy |
| 2024-03-01 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2023-12-21 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2023-10-30 | Iniziato | Wells Fargo | Overweight |
| 2023-05-26 | Downgrade | BofA Securities | Buy → Neutral |
| 2023-05-25 | Downgrade | JP Morgan | Overweight → Neutral |
| 2022-09-16 | Iniziato | Jefferies | Buy |
| 2022-09-09 | Iniziato | BTIG Research | Buy |
| 2021-11-30 | Iniziato | H.C. Wainwright | Buy |
| 2021-09-23 | Iniziato | Cantor Fitzgerald | Overweight |
| 2021-01-26 | Iniziato | Needham | Buy |
| 2020-08-18 | Iniziato | BofA Securities | Buy |
| 2020-08-18 | Iniziato | Cowen | Outperform |
| 2020-08-18 | Iniziato | JP Morgan | Overweight |
Mostra tutto
Annexon Inc Borsa (ANNX) Ultime notizie
Annexon (ANNX) director William Waddill receives 65,000 stock options grant - Stock Titan
Annexon (NASDAQ: ANNX) director receives 65,000-share stock option grant - Stock Titan
[Form 4] Annexon, Inc. Insider Trading Activity - Stock Titan
Annexon (ANNX) director Bettina Cockroft awarded 65,000 stock options at $4.70 - Stock Titan
Annexon (ANNX) grants director Jung Choi 65,000 stock options at $4.70 - Stock Titan
Annexon (ANNX) director William Carson receives 65,000 stock options at $4.70 - Stock Titan
Annexon (NASDAQ: ANNX) EVP exercises stock options, lifts stake to 184,807 shares - Stock Titan
ANNX Q1 2026 Earnings: Narrower-than-Expected Loss Drives Positive Stock ReactionEarnings Sentiment Score - newsline.com
Annexon Inc. (ANNX) Holds Steady Near Support as Biotech Sector Faces HeadwindsRisk Parity Rebalance - newsline.com
ANNX News | ANNEXON INC (NASDAQ:ANNX) - ChartMill
Annexon Stockholders Approve Directors, Compensation and Share Increase - TipRanks
Annexon (NASDAQ: ANNX) reports 2026 annual meeting vote outcomes - Stock Titan
Annexon Inc. (ANNX) Gains 2.13% as Biotech Stock Holds Above Key SupportCounter Trend Trade - newsline.com
ANNX: All proposals passed as late-stage therapies advance and cash runway extends into 2027 - TradingView
Annexon Inc Annual Shareholders Meeting Transcript - GuruFocus
Annexon eyes 'win season' with Q4 vision trial data, GBS filings ahead - MSN
Annexon maps 3 big pipeline catalysts ahead of Q4 vision-drug readout - MSN
Annexon Eyes ‘Win Season’ With Q4 Vision Trial Data, GBS Filings Ahead - MarketBeat
Annexon Inc at Goldman Sachs Healthcare Conference Transcript - GuruFocus
Exploring 3 High Growth Tech Stocks in the US Market - simplywall.st
ANNX Stock Price, Quote & Chart - ChartMill
Annexon Maps 3 Big Pipeline Catalysts Ahead of Q4 Vision-Drug Readout - sharewise.com
ANNX: Three major clinical data readouts expected in 2024, each with strong differentiation - TradingView
Annexon Inc. (ANNX) Holds Steady Near Support as Consolidation ContinuesOversold Bounce Ideas - newsline.com
ANNX Q1 2026 Earnings: EPS Beat Guidance as Clinical Progress ContinuesSubscription Growth Report - The Legal Advocate
Annexon(ANNX.US) Director Buys US$3.32 Million in Common Stock - Moomoo
Annexon Inc. (ANNX) Shows Modest Gain: Biotech Stock Tests Key LevelsWide Range Bar - The Legal Advocate
Insider Purchase: Director at $ANNX Buys 613,497 Shares - Moomoo
Annexon director Muneer Satter buys $3.3m in common stock By Investing.com - Investing.com South Africa
Annexon director Muneer Satter buys $3.3m in common stock - Investing.com
Director-linked fund buys 613K Annexon (ANNX) shares in open market - Stock Titan
ANNX Q1 2026 Earnings: EPS Beat Driven by Cost Control Amid Pre-Revenue StageCFO Commentary Report - The Legal Advocate
ANNX Q1 2026 Earnings: EPS Surpasses Estimates by 22% as Biotech Advances PipelineEarnings Preview - The Legal Advocate
Annexon Insider Bought Shares Worth $3,319,019, According to a Recent SEC Filing - Moomoo
ANNX Q1 2026 Earnings: EPS Beat Surprise as Clinical-Stage Biotech Tightens Cost ControlPost-Earnings Drift - newsline.com
Annexon to Participate in Upcoming June Investor Conferences - Investing News Network
Annexon CEO Douglas Love to speak at Jefferies and Goldman Sachs in June - Stock Titan
ANNX Q1 2026 Earnings: EPS Beat Lifts Shares as Pre-Revenue Biotech AdvancesEarnings Revision Report - newsline.com
ANNX Q1 2026 Earnings: Clinical Pipeline Progress Drives EPS Beat as Stock Dips on Broader Biotech HeadwindsGuidance Accuracy Score - newsline.com
Annexon Inc at JPMorgan Healthcare Conference Transcript - GuruFocus
Redmile Group, LLC's Annexon Inc(ANNX) Holding History - GuruFocus
Annexon Reports Inducement Grants to New Employees under Nasdaq Listing Rule 5635(4) - marketscreener.com
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Is Annexon (NASDAQ:ANNX) In A Good Position To Deliver On Growth Plans? - Moomoo
Annexon (ANNX) insiders/affiliates report 8.7M-share stake (5.4%) - Stock Titan
What Annexon (ANNX)'s -2.61% Decline Means for Investors 2026-05-15Pullback Trade - newsline.com
Wall Street analysts see a 165.52% upside in Annexon (ANNX): Can the stock really move this high? - MSN
Annexon, Inc.common stock (NQ: ANNX - FinancialContent
Annexon Inc at Bank of America Global Healthcare Conference Transcript - GuruFocus
Annexon Highlights Q4 Geographic Atrophy Data, GBS Filing Plans at BofA Conference - sharewise.com
Director William Carson Acquires Additional Shares of Annexon In - GuruFocus
Annexon Inc Azioni (ANNX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Annexon Inc Azioni (ANNX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Satter Muneer A | Director |
May 28 '26 |
Buy |
5.41 |
613,497 |
3,319,019 |
10,342,134 |
| Carson William H. | Director |
May 11 '26 |
Buy |
5.78 |
8,000 |
46,240 |
78,405 |
| Carson William H. | Director |
Apr 10 '26 |
Buy |
6.20 |
8,000 |
49,600 |
70,405 |
| Carson William H. | Director |
Mar 10 '26 |
Buy |
5.67 |
8,000 |
45,360 |
62,405 |
| Dananberg Jamie | CHIEF MEDICAL OFFICER |
Mar 02 '26 |
Sale |
5.43 |
5,820 |
31,603 |
123,582 |
| Overdorf Michael | EVP & CHIEF BUSINESS OFFICER |
Mar 02 '26 |
Sale |
5.42 |
4,339 |
23,517 |
182,625 |
| Yednock Ted | EVP & CHIEF INNOVATION OFFICER |
Mar 02 '26 |
Sale |
5.42 |
5,566 |
30,168 |
154,161 |
| ARTIS DEAN RICHARD | EVP & CHIEF SCIENTIFIC OFFICER |
Mar 02 '26 |
Sale |
5.43 |
5,894 |
32,004 |
180,093 |
| Lew Jennifer | EVP & CHIEF FINANCIAL OFFICER |
Mar 02 '26 |
Sale |
5.42 |
5,565 |
30,162 |
170,700 |
2.60%
0.94%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):